Related Experiment Videos
Bleeding risks associated with inheritance of the Quebec platelet disorder
Heather McKay1, Francine Derome, M Anwar Haq
1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Blood
|March 18, 2004
Summary
Quebec platelet disorder (QPD) is a bleeding disorder linked to increased urokinase-type plasminogen activator. Fibrinolytic inhibitors can effectively manage bleeding risks associated with QPD.
Area of Science:
- Hematology
- Genetics
- Bleeding Disorders
Background:
- Quebec platelet disorder (QPD) is an autosomal dominant inherited bleeding disorder.
- It is characterized by elevated platelet urokinase-type plasminogen activator (u-PA) and alpha-granule protein degradation.
- Understanding the clinical manifestations and bleeding risks is crucial for patient management.
Purpose of the Study:
- To determine the bleeding risks and common clinical manifestations in individuals with Quebec platelet disorder.
- To assess the impact of QPD on lifestyle and the effectiveness of treatments.
Main Methods:
- A history questionnaire was administered to 127 relatives from a QPD-affected family.
- Data was collected blinded to affected status, confirmed by u-PA and fibrinogen degradation assays.
- Odds ratios (ORs) and bleeding scores were calculated to identify significant risk factors.
Main Results:
- Affected individuals (n=23) had significantly higher bleeding scores compared to unaffected relatives (n=104).
- High likelihood (OR > 20) of lifestyle-altering bleeding, large bruises, joint bleeds, prolonged bleeding (>24 hours), and use of fibrinolytic inhibitors was observed.
- Excessive bleeding occurred only when fibrinolytic inhibitors were not used during hemostatic challenges.
Conclusions:
- Quebec platelet disorder presents with increased bleeding risks and specific clinical features.
- Bleeding manifestations in QPD can be significantly modified and managed with fibrinolytic inhibitors.